首页> 外文期刊>Clinical nuclear medicine >Resolution of Hyperreninemia, Secondary Hyperaldosteronism, and Hypokalemia With Lu-177-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy in a Patient With Pancreatic Neuroendocrine Tumor
【24h】

Resolution of Hyperreninemia, Secondary Hyperaldosteronism, and Hypokalemia With Lu-177-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy in a Patient With Pancreatic Neuroendocrine Tumor

机译:Lu-177-DOTATATE诱导和维持肽受体放射性核素治疗胰腺神经内分泌肿瘤患者的高肾素血症,继发性醛固酮过多症和低血钾症

获取原文
获取原文并翻译 | 示例
           

摘要

A 54-year-old woman presented with a history of nausea, vomiting, diarrhea, and recurrent episodes of severe hypokalemia requiring hospitalization. Imaging revealed a pancreatic mass with liver metastases, histologically confirmed to be a neuroendocrine tumor. Elevated active renin and aldosterone levels were identified, and the patient was treated with 4 induction cycles of Lu-177-DOTATATE, which resolved the diarrhea, nausea, and hypokalemia, and normalized the renin and aldosterone levels. After 3 additional maintenance Lu-177-DOTATATE treatments, the pancreatic tumor had decreased in size, was deemed operable, and was resected. She remains on maintenance Lu-177-DOTATATE therapy with progression-free survival of 45 months thus far.
机译:一名54岁的女性,有恶心,呕吐,腹泻和严重低钾血症反复发作的历史,需要住院治疗。影像学检查发现胰腺有肝脏转移,在组织学上证实是神经内分泌肿瘤。识别出活动性肾素和醛固酮水平升高,并用4个诱导周期的Lu-177-DOTATATE诱导患者,从而解决了腹泻,恶心和低钾血症,并使肾素和醛固酮水平正常化。经过3次额外的Lu-177-DOTATATE维持治疗后,胰腺肿瘤缩小,被认为可手术切除。她一直保持Lu-177-DOTATATE维持治疗,迄今为止无进展生存期为45个月。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号